You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

À propos des lignes directrices

Displaying Guidelines

146 articles

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Document Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Document Status: Current
ID: GL-END-C50-35

Aug 2023

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Document Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Document Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Document Status: Current
ID: GL END 9-10
Version: 2

Aug 2022

Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy

Document Status: Current
ID: 12-15

Dec 2015

Best Practice Recommendations for Regimen Development and Maintenance

Document Status: Current
ID: GL-C50-25

Feb 2016

Biochemotherapy for the Treatment of Metastatic Malignant Melanoma

Document Status: Archived
ID: 8-3

Sep 2011

Cancer and the Health Effects of Cannabis and Cannabinoids: An update of the systematic review by the National Academies of Sciences, Engineering, and Medicine (2017) Consensus Study Report

Document Status: Current
ID: ES 23-2
Version: N/A

Jun 2020

Cancer Care Ontario Beyond-Use Date Recommendations Report

Document Status: Current
ID: N/A
Version: 1

Mar 2018

Cancer Care Ontario’s Focus on Take-Home Cancer Drugs and Community Practice

Document Status: Current
ID: GL-C50-17

Jan 2015

Capecitabine in Stage IV Breast Cancer

Document Status: Archived
ID: 1-16
Version: 2

Sep 2011